矿物质皮质类受体对手:心力衰竭的支柱药物
Rishi Sethi1, Rajat Jain2, Ram A Raj3
1Head of Department and Interventional Cardiologist, Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India, Corresponding Author.
The Journal of the Association of Physicians of India
|March 12, 2026
概括
矿物质皮质类受体抗剂 (MRAs) 对于治疗心力衰竭 (HF) 具有减少喷射率 (HFrEF) 的治疗至关重要. 这些药物,如螺旋和eplerenone,通过阻断阿尔多素的作用,减少死亡率和住院治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 矿物质皮质类受体抗剂 (MRAs) 在治疗心力衰竭 (HF) 中至关重要,特别是在减少射出分数 (HFrEF) 的患者中.
- MRAs对抗阿尔多素,减少水分保留,心肌纤维化和神经激素激活,这些都推动了HF的进展.
- 类固醇MRAs,spironolactone和eplerenone是已建立的疗法,主要临床试验支持.
研究的目的:
- 审查类固醇MRAs的药理机制.
- 总结临床试验证据,支持在高频率治疗中使用MRA.
- 讨论螺旋和eplerenone的安全性和耐受性概况.
主要方法:
- 标志性临床试验 (RALES,EPHESUS,EMPHASIS-HF) 的文献综述. 这是一篇关于临床试验的文章.
- 对药理作用和受体结合特性的分析.
- 检查安全数据和副作用概况.
主要成果:
- 类固醇MRA显著降低HFrEF患者的死亡率,住院和症状.
- 螺旋龙,虽然有效,但由于非选择性结合,具有荷尔蒙副作用.
- 埃普莱伦提供了更好的耐受性与更大的受体特异性.
结论:
- 类固醇MRA在现代心力衰竭治疗中不可或缺.
- 螺旋和eplerenone之间的选择取决于有效性和耐受性考虑.
- 持续使用MRA对于全面的高频管理至关重要.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K